Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026
Drug Policy / Regulatory

CDE Releases 76th Batch of Chemical Generic Reference Preparations

Fineline Cube Nov 17, 2023

The Center for Drug Evaluation (CDE) has released the 76th batch of chemical generic reference...

Company Drug

Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study

Fineline Cube Nov 17, 2023

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II...

Company Drug

Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene

Fineline Cube Nov 17, 2023

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...

Deals R&D

University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University

Fineline Cube Nov 17, 2023

The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established...

Company

BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou

Fineline Cube Nov 17, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule...

Company Drug

Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia

Fineline Cube Nov 17, 2023

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...

Company Deals

Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services

Fineline Cube Nov 17, 2023

Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...

Company Drug

Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy

Fineline Cube Nov 17, 2023

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...

Company Deals

Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen

Fineline Cube Nov 17, 2023

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...

Company Deals

Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry

Fineline Cube Nov 16, 2023

Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...

Company Drug

SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA

Fineline Cube Nov 16, 2023

SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...

Company

Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Nov 16, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...

Company Medical Device

Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval

Fineline Cube Nov 16, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced...

Company Deals

Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies

Fineline Cube Nov 16, 2023

Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...

Company Deals

AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management

Fineline Cube Nov 16, 2023

US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/Ritonavir NDA Accepted by NMPA

Fineline Cube Nov 16, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its...

Company Deals

Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment

Fineline Cube Nov 16, 2023

Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...

Company Deals

Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal

Fineline Cube Nov 16, 2023

Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...

Company Drug

China’s NMPA Accepts EOC Pharma Group’s Filing for Vascepa (Icosapent Ethyl) for Review

Fineline Cube Nov 15, 2023

The China-based EOC Pharma Group has achieved a significant milestone with the National Medical Products...

Company Deals

Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition

Fineline Cube Nov 15, 2023

The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...

Posts pagination

1 … 482 483 484 … 705

Recent updates

  • GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled
  • Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor
  • WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation
  • Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials
  • Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.